Dabigatran
Composition
The formulation Contains dabigatran etexilate mesilate as the active ingredient.
Indications
Prevention of stroke and systemic embolism in non-valvular atrial fibrillation, treatment and prevention of deep vein
Side effects
gastrointestinal upset, bleeding, and hematoma formation
Precautions
Use with caution in patients with renal impairment or a history of bleeding disorders. Monitor renal function and signs of bleeding regularly.
Contraindications
Severe hepatic dysfunction, bone marrow suppression
Dosage and administration
typically taken twice daily with or without food
Countries
USA, Canada, EU
Available Forms
Capsules